- Home
- GLPG vs INSP Comparison
GLPG vs INSP Comparison
Compare GLPG & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLPG | INSP |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | Belgium | United States |
| Employees | 704 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GLPG | INSP |
|---|---|---|
| Price | $29.98 | $51.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 16 |
| Target Price | $36.50 | ★ $101.07 |
| AVG Volume (30 Days) | 150.8K | ★ 828.9K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 179.43 |
| EPS | N/A | ★ 4.89 |
| Revenue | N/A | ★ $82,050,000.00 |
| Revenue This Year | N/A | $8.20 |
| Revenue Next Year | N/A | $8.44 |
| P/E Ratio | ★ N/A | $10.31 |
| Revenue Growth | N/A | ★ 62.18 |
| 52 Week Low | $22.59 | $48.30 |
| 52 Week High | $37.78 | $164.02 |
Technical Indicators
Market Signals| Indicator | GLPG | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 30.94 |
| Support Level | $28.78 | N/A |
| Resistance Level | $33.67 | $84.26 |
| Average True Range (ATR) | 0.86 | 2.80 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 30.85 | 23.04 |
Price Performance
Historical ComparisonAbout GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About INSP Inspire Medical Systems Inc.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.